Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 46Neoplasms 10Prostatic Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 6Neoplasm Metastasis 6Carcinoma, Ovarian Epithelial 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms, Male 5Sarcoma 4Ovarian Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Stomach Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Lung Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Kidney Neoplasms 3Endometrial Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Burkitt Lymphoma 3Wilms Tumor 2Testicular Neoplasms 2Teratoma 2

Interventions

Cisplatin 13Paclitaxel 10Ifosfamide 10Etoposide 10Filgrastim 8Bleomycin 8Carboplatin 7pegfilgrastim 3Peripheral Blood Stem Cell Transplantation 3Granulocyte Colony-Stimulating Factor 3liposomal amphotericin B 2etoposide phosphate 2Therapeutics 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Drug Therapy 2Cyclophosphamide 2sargramostim 1sabarubicin 1ixabepilone 1aldesleukin 1Vincristine 1Vinblastine 1Thiotepa 1Taxes 1Surgical Procedures, Operative 1Sunitinib 1Standard of Care 1Specimen Handling 1Ribavirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Endodermal Sinus Tumor × ixabepilone × Clear all
NCT00070096 2013-06-24

Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors

National Cancer Institute (NCI)

Phase 2 Completed
29 enrolled
CNSGenitourinaryGynecologic

Testicular Germ Cell Tumor, Ovarian Neoplasms, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Carcinoma, Embryonal, Seminoma, Endodermal Sinus Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡